Skip to main content
. 2022 Jun 8;12:903832. doi: 10.3389/fonc.2022.903832

Figure 5.

Figure 5

Cu-B suppresses tumor development in a NOD-SCID murine model of human melanoma (A). Representative photographs of Cu-B treated NOD-SCID mice bearing A375 xenografts and the excised tumors. (B) Cu-B represses the tumor volume in Cu-B treated melanoma-bearing mice. (C) Cu-B treatment unalters the bodyweights of mice throughout the study period. (D) Histopathological evaluation of tumor tissue isolated from mice groups. Formalin-fixed cryosections were H and E stained. (E) IHC analysis on the expression of PCNA in tumor tissues of mice groups. (F) The apoptosis induced by Cu-B in the tumor tissues was confirmed by TUNEL assay (G) Immunoblot analysis demonstrating enhanced cleavage of PARP in the tumor lysates of Cu-B treated mice. (H–J) Immunoblot analysis showing the effect of Cu-B on key survival signals in melanoma, B- RAFV600E, p-MEK1/2, p-ERK1/2, p-STAT3, c-MYC, Cyclin-D1, and MITF-M, as evidenced in the tumor lysates. (K) IHC analysis on the expression of B- RAFV600E, p-MEK1/2, p-ERK1/2, p-STAT3, and c-MYC in tumor tissues of mice groups. Data are representative of three independent experiments (Mean±SEM) and P-values are calculated using one-way ANOVA. ****P ≤0.0001, ***P ≤0.001, **P ≤0.01, *P ≤0.1 and ns ≥ 0.05.